WeDoctor Accelerates Pre-IPO Reorganization, Focusing on 'Tri-Med Integrated' Core Strategy

VCBeat (WeChat ID: vcbeat) reporters have just learned from insiders at WeDoctor that, in order to implement the core strategy of “Three-Medical Integration,” WeDoctor Group announced its largest organizational upgrade in two years internally on March 20.Focusing on core strategy, platformizing business operations, and rejuvenating the management team have become the key themes of this organizational upgrade.

According to the latest data released by CB Insights, WeDoctor is the largest unicorn in the healthcare technology industry. Building on its existing businesses—WeDoctor Cloud, WeMedicare, WePharma, and WeInsurance—WeDoctor has announced an upgrade to focus on creating an open “Three-Medical Linkage” platform. Based on this platform, the company will establish two major business lines: G2G (government-purchased services) and B2C (market-purchased services).

According to VCBeat, the San-Yi-Lian platform integrates the strengths of WeDoctor, the Haixi Pharmaceutical Platform, and Yilianzhong in healthcare, pharmaceuticals, and medical insurance, thereby establishing five core capabilities: tiered diagnosis and treatment, centralized procurement of drugs and medical devices, smart medical insurance, interoperability of data across healthcare, pharmaceuticals, and medical insurance, and commercial health insurance.

Internally, the platform is responsible for advancing data interoperability, product integration, and data intelligence across the three core sectors: healthcare services, pharmaceuticals, and health insurance. Externally, it addresses the needs of provincial, municipal, and county-level governments for integrated reforms in these three areas, breaking down silos to alleviate systemic pain points.

The 2G business line primarily serves governments at all levels and hospitals, helping them build regional healthcare communities and improve the service efficiency of the “three medicals” (medical care, health insurance, and pharmaceuticals).

As of now, the 2G Business Group’s “Jiwei Cloud” business has deployed over 300 cloud-based mobile clinic vehicles, covering nearly 10 million users across five provinces and becoming China’s “mobile secondary hospitals” at the grassroots level. The Haixi Pharmaceutical Platform recorded a transaction volume exceeding RMB 48 billion in 2018 and has recently successfully completed the first national order under the “4+7” pilot program for centralized drug procurement.

"Wei Yi Bao" has over 11 million paying users, and the intelligent medical insurance handling platform serves more than 20 provinces, covering a population of over 450 million.

The 2C Business Group integrates the WeDoctor Portal, WeDoctor General Practice Centers, Wuzhen Internet Hospital (Specialty Care), the Internet Traditional Chinese Medicine Clinic, and the WeDoctor Commercial Center. Focusing on membership services and healthcare consumption, it provides users with “online + offline” and “general practice + specialty care” private doctor services. The platform has cumulatively served 810 million user visits.

Furthermore, with the “Three-Medical Integration” strategy at its core, WeDoctor participated in founding Zhongjian Investment Capital. Leveraging industrial capital as a means, it identifies, incubates, and supports the technological and pharmaceutical-insurance capabilities required for the Three-Medical Integration platform’s operations, jointly building an open ecosystem for the healthcare industry.

Following this adjustment, WeDoctor’s business lines will become more focused, forming a technology-centric “Three-Medical Linkage” platform and 2G and 2C business lines that facilitate interoperability among healthcare services, pharmaceuticals, and insurance. This change may indicate that WeDoctor is taking further steps to prepare for separate listings on the Hong Kong Stock Exchange and the A-share market.

Alongside this organizational upgrade, WeDoctor has appointed a group of young, frontline business key personnel as heads of business lines. Building on this foundation, the company announced the launch of the “Torchbearer Succession Plan,” under which 50 individuals will be selected from core business talent to assume leadership roles in key positions, with incentives including salary adjustments and stock options. Additionally, a “Honorary Retirement Plan” has been introduced for eligible senior executives.

It is understood that this organizational upgrade was led by Savio Kwan, Chairman of the Micro Medical Group Organizational Committee. Formerly President and Chief Operating Officer of Alibaba, Savio Kwan, often referred to as the “Godmother of Alibaba,” helped Alibaba establish an organizational structure and value system capable of supporting a trillion-dollar market capitalization through several decisive reforms. With Savio Kwan at the helm, the industry’s expectations for Micro Medical Group’s current organizational upgrade and subsequent transformations have grown.